poisar

Stocks · News reference

Smith+Nephew's CARTIHEAL AGILI-C Implant Now Commercially Available In Europe; Randomized Trial Data Show Superior Pain Relief And Functional Gains Over 5 Years Versus Debridement Or Microfracture

Benzinga Newsdesk
More stocks newsConnected markets

Reference Details

Connected Markets

Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.

SNN
Source
benzinga
Observed
Checked
Cadence
Captured once, then retained as an archive reference
Status
fresh

Keep reading

  1. Na

    Smith+Nephew lancia in Europa CARTIHEAL™ AGILI-C™, l’innovativo impianto per la riparazione della cartilagine, che sarà presentato all’ICRS Summit in Portogallo.

    Smith+Nephew announced the commercial launch of CARTIHEAL AGILI-C, an innovative cartilage repair implant, across Europe. The aragonite-based scaffold will be presented at the ICRS Summit in Portugal (October 8-10). A randomized controlled trial published in the American Journal of Sports Medicine demonstrated clinical superiority over standard surgical care, with patients showing improved pain relief and functional outcomes over 5 years. The implant will initially be available in 8 European countries with plans for further expansion.

    SNN
  2. Smith+Nephew

    Smith+Nephew’s revolutionary CARTIHEAL™ AGILI-C™ Cartilage Repair Implant launches in Europe; to be featured at ICRS Summit in Portugal

    Smith+Nephew announced the commercial availability of its CARTIHEAL AGILI-C cartilage repair implant in Europe, following its 2024 US launch. The aragonite-based implant demonstrated clinical superiority over standard care in a multicenter randomized controlled trial, showing superior pain relief and functional gains over 5 years. The product will initially be available in 12 European countries.

    SNN
  3. Na

    Smith+Nephew Launches EVOS PELVIC System to Advance Trauma Care

    Smith+Nephew (SNN) launched the EVOS PELVIC Plating System to expand its orthopedic trauma portfolio into pelvic and acetabular fracture management. The system features dedicated plates, cannulated screws, and specialized instruments designed to improve surgical efficiency. The global pelvic trauma market is projected to grow from $2.81 billion in 2025 to $4.79 billion by 2034 at a 6.1% CAGR, driven by increased high-energy fractures and wider adoption of surgical fixation protocols.

    SNNGMEDVCYTWST